These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 22874768)

  • 1. Rescue screens with secreted proteins reveal compensatory potential of receptor tyrosine kinases in driving cancer growth.
    Harbinski F; Craig VJ; Sanghavi S; Jeffery D; Liu L; Sheppard KA; Wagner S; Stamm C; Buness A; Chatenay-Rivauday C; Yao Y; He F; Lu CX; Guagnano V; Metz T; Finan PM; Hofmann F; Sellers WR; Porter JA; Myer VE; Graus-Porta D; Wilson CJ; Buckler A; Tiedt R
    Cancer Discov; 2012 Oct; 2(10):948-59. PubMed ID: 22874768
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of MET and EGFR suppresses proliferation of malignant mesothelioma cells.
    Kawaguchi K; Murakami H; Taniguchi T; Fujii M; Kawata S; Fukui T; Kondo Y; Osada H; Usami N; Yokoi K; Ueda Y; Yatabe Y; Ito M; Horio Y; Hida T; Sekido Y
    Carcinogenesis; 2009 Jul; 30(7):1097-105. PubMed ID: 19380521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CUDC-101, a multitargeted inhibitor of histone deacetylase, epidermal growth factor receptor, and human epidermal growth factor receptor 2, exerts potent anticancer activity.
    Lai CJ; Bao R; Tao X; Wang J; Atoyan R; Qu H; Wang DG; Yin L; Samson M; Forrester J; Zifcak B; Xu GX; DellaRocca S; Zhai HX; Cai X; Munger WE; Keegan M; Pepicelli CV; Qian C
    Cancer Res; 2010 May; 70(9):3647-56. PubMed ID: 20388807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer.
    De Bacco F; Luraghi P; Medico E; Reato G; Girolami F; Perera T; Gabriele P; Comoglio PM; Boccaccio C
    J Natl Cancer Inst; 2011 Apr; 103(8):645-61. PubMed ID: 21464397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.
    Hochgräfe F; Zhang L; O'Toole SA; Browne BC; Pinese M; Porta Cubas A; Lehrbach GM; Croucher DR; Rickwood D; Boulghourjian A; Shearer R; Nair R; Swarbrick A; Faratian D; Mullen P; Harrison DJ; Biankin AV; Sutherland RL; Raftery MJ; Daly RJ
    Cancer Res; 2010 Nov; 70(22):9391-401. PubMed ID: 20861192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foretinib (GSK1363089), a multi-kinase inhibitor of MET and VEGFRs, inhibits growth of gastric cancer cell lines by blocking inter-receptor tyrosine kinase networks.
    Kataoka Y; Mukohara T; Tomioka H; Funakoshi Y; Kiyota N; Fujiwara Y; Yashiro M; Hirakawa K; Hirai M; Minami H
    Invest New Drugs; 2012 Aug; 30(4):1352-60. PubMed ID: 21655918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of 4-benzylamino-substituted α-carbolines as a novel class of receptor tyrosine kinase inhibitors.
    Krug M; Wichapong K; Erlenkamp G; Sippl W; Schächtele C; Totzke F; Hilgeroth A
    ChemMedChem; 2011 Jan; 6(1):63-72. PubMed ID: 21140395
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell lines expressing recombinant transmembrane domain-activated receptor kinases as tools for drug discovery.
    Weber H; Müller D; Müller M; Ortiz A; Birkle M; Umber S; Ketterer C; Siedentopf O; Feger D; Totzke F; Kubbutat M; Schaechtele C; Ballmer-Hofer K; Ehlert JE; Graeser R
    J Biomol Screen; 2014 Dec; 19(10):1350-61. PubMed ID: 25260782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB; Hynes NE; Lane HA
    Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.
    Pan BS; Chan GK; Chenard M; Chi A; Davis LJ; Deshmukh SV; Gibbs JB; Gil S; Hang G; Hatch H; Jewell JP; Kariv I; Katz JD; Kunii K; Lu W; Lutterbach BA; Paweletz CP; Qu X; Reilly JF; Szewczak AA; Zeng Q; Kohl NE; Dinsmore CJ
    Cancer Res; 2010 Feb; 70(4):1524-33. PubMed ID: 20145145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
    Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer.
    Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S
    Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade of EGFR and ErbB2 by the novel dual EGFR and ErbB2 tyrosine kinase inhibitor GW572016 sensitizes human colon carcinoma GEO cells to apoptosis.
    Zhou Y; Li S; Hu YP; Wang J; Hauser J; Conway AN; Vinci MA; Humphrey L; Zborowska E; Willson JK; Brattain MG
    Cancer Res; 2006 Jan; 66(1):404-11. PubMed ID: 16397255
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Crosstalk in Met receptor oncogenesis.
    Lai AZ; Abella JV; Park M
    Trends Cell Biol; 2009 Oct; 19(10):542-51. PubMed ID: 19758803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER3 and mutant EGFR meet MET.
    Arteaga CL
    Nat Med; 2007 Jun; 13(6):675-7. PubMed ID: 17554333
    [No Abstract]   [Full Text] [Related]  

  • 17. Conversion from the "oncogene addiction" to "drug addiction" by intensive inhibition of the EGFR and MET in lung cancer with activating EGFR mutation.
    Suda K; Tomizawa K; Osada H; Maehara Y; Yatabe Y; Sekido Y; Mitsudomi T
    Lung Cancer; 2012 Jun; 76(3):292-9. PubMed ID: 22133747
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibitors of epidermoid growth factor receptor suppress cell growth and enhance chemosensitivity of nasopharyngeal cancer cells in vitro.
    Hsu CH; Gao M; Chen CL; Yeh PY; Cheng AL
    Oncology; 2005; 68(4-6):538-47. PubMed ID: 16037687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.
    Petti C; Picco G; Martelli ML; Trisolini E; Bucci E; Perera T; Isella C; Medico E
    Oncotarget; 2015 Jan; 6(1):221-33. PubMed ID: 25473895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of receptor tyrosine kinase (RTK) phosphorylation by immunoblotting.
    McDermott M; O'Donovan N
    Methods Mol Biol; 2015; 1233():3-14. PubMed ID: 25319884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.